Q4 EPS Estimates for bluebird bio Lifted by Leerink Partnrs

bluebird bio, Inc. (NASDAQ:BLUE) – Leerink Partnrs increased their Q4 2024 EPS estimates for bluebird bio in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings per share of ($4.42) for the quarter, up from their prior estimate of ($4.47). The consensus estimate for bluebird bio’s current full-year earnings is ($27.17) per share. Leerink Partnrs also issued estimates for bluebird bio’s FY2025 earnings at ($6.42) EPS.

Several other research analysts also recently commented on the stock. StockNews.com initiated coverage on shares of bluebird bio in a research note on Friday, December 20th. They issued a “sell” rating on the stock. Bank of America downgraded shares of bluebird bio from a “buy” rating to a “neutral” rating and decreased their price target for the company from $60.00 to $10.00 in a research note on Friday, November 15th. Barclays increased their price objective on bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 31st. JPMorgan Chase & Co. cut bluebird bio from a “neutral” rating to an “underweight” rating in a report on Friday, November 15th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $80.00 price target on shares of bluebird bio in a research note on Friday, November 15th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, bluebird bio has an average rating of “Hold” and a consensus price target of $49.14.

bluebird bio Price Performance

NASDAQ:BLUE opened at $7.87 on Friday. The firm has a market capitalization of $76.50 million, a price-to-earnings ratio of -0.21 and a beta of 0.68. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. The business has a 50 day simple moving average of $8.13 and a 200-day simple moving average of $11.97. bluebird bio has a 1 year low of $5.80 and a 1 year high of $38.40.

Institutional Investors Weigh In On bluebird bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its stake in bluebird bio by 315.3% in the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock valued at $1,223,000 after buying an additional 1,013,144 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in bluebird bio by 2,270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 355,562 shares during the last quarter. FMR LLC lifted its stake in bluebird bio by 8.1% in the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after purchasing an additional 186,903 shares in the last quarter. Barclays PLC boosted its holdings in shares of bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 184,605 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in bluebird bio by 3.7% during the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after buying an additional 166,771 shares in the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.